In one 2023 study funded by Novo Nordisk, scientists found that participants without type 2 diabetes who took oral semaglutide every day for 68 weeks lost an average of 15 percent of their body weight
It is an obesity therapeutics market, an incretin therapy market, a cardiometabolic pipeline market, and an investment theme that touches nearly every major pharmaceutical growth strategy
Diabetologia 65(Suppl 1):S288S288 Samms RJ, Zhang G, He W et al (2022) Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Nausea, vomiting, and diarrhea from GLP-1 use compound the risk of dehydration
To view a copy of this licence, visit About this article Cite this article Murphy, A., Shyanti, R.K
They belong to completely different categories: Phentermine = stimulant appetite suppressant GLP-1 = hormone-based metabolic treatment Which One Should You Choose